By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Abbott Laboratories et al. v. Watson Pharmaceuticals et al.
1:11-cv-00607; filed July 8, 2011 in the District Court of Delaware
• Plaintiffs: Abbott Laboratories; Abbott Respiratory LLC
• Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc. – Florida; Watson Pharma Inc.
Infringement of U.S. Patent Nos. 6,129,930 ("Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia at Night," issued October 10, 2000), 6,406,715 ("Intermediate Release Nicotinic Acid Compositions for Treating Hyperlipidemia Having Unique Urinary Metabolite Profiles," issued June 18, 2002), 6,676,967 ("Methods for Reducing Flushing in Individuals Being Treated with Nicotinic Acid for Hyperlipidemia," issued January 13, 2004), 6,746,691 ("Intermediate Release Nicotinic Acid Compositions for Treating Hyperlipidemia Having Unique Biopharmaceutical Characteristics," issued June 8, 2004), 7,011,848 ("Hydrophobic Component Free Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor," issued March 14, 2006), 6,818,229 ("Intermediate Release Nicotinic Acid Compositions for Treating Hyperlipidemia," issued November 16, 2004), 6,080,428 ("Nicotinic Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor," issued June 27, 2000), and 6,469,035 ("Methods of Pretreating Hyperlipidemic Individuals with a Flush Inhibiting Agent Prior to the Start of Single Daily Dose Nicotinic Acid Therapy to Reduce Flushing Provoked by Nicotinic Acid," issued October 22, 2002) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Abbott's Simcor® (niacin extended release / simvastatin tablets, used to treat hypercholesterolemia). View the complaint here.
Pfizer Inc. et al. v. Apotex Inc. et al.
1:11-cv-00606; filed July 8, 2011 in the District Court of Delaware
• Plaintiffs: Pfizer Inc.; Warner-Lambert Co. LLC; CP Pharmaceuticals International CV; Northwestern University
• Defendants: Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent Nos. 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001) and 5,563,175 ("GABA and L-Glutamic Acid Analogs for Antiseizure Treatment," issued October 8, 1996) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the complaint here.
Ferring B.V. v. Apotex, Inc. et al.
3:11-cv-00485; filed July 8, 2011 in the District Court of Nevada
• Plaintiff: Ferring B.V.
• Defendants: Apotex, Inc.; Apotex Corp.
Infringement of U.S. Patent No. 7,947,739 ("Tranexamic Acid Formulations," issued May 24, 2011) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic acid, used to treat heavy menstrual bleeding). View the complaint here.
Purdue Pharma L.P. et al. v. Sandoz Inc.
1:11-cv-04694; filed July 7, 2011 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies; Board of Regents of The University of Texas System; Grunenthal GMBH
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 6,488,963 ("Hot-Melt Extrudable Pharmaceutical Formulation," issued December 3, 2002), 7,674,799 ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title, issued March 9, 2010), 7,683,072 (same title, issued March 23, 2010), and 7,776,314 ("Abuse-Proofed Dosage System," issued August 17, 2010) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Shire LLC et al. v. Watson Laboratories Inc.
2:11-cv-05565; filed July 6, 2011 in the Central District of California
• Plaintiffs: Shire LLC; Shire Development Inc.
• Defendant: Watson Laboratories Inc.
Infringement of U.S. Patent Nos. 7,105,486 ("Abuse-resistant amphetamine compounds," issued September 12, 2006), 7,223,735 ("Abuse resistant lysine amphetamine compounds," issued May 29, 2007), and 7,700,561 ("Abuse-resistant amphetamine prodrugs," issued April 20, 2010) following a Paragraph IV certification as part of Waton's filing of an ANDA to manufacture a generic version of Shire's Vyvanse® (lisdexamfetamine dimesylate, used to treat Attention Deficit Hyperactivty Disorder). View the complaint here.
Comments